|

Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer

RECRUITINGN/ASponsored by Istanbul University
Actively Recruiting
PhaseN/A
SponsorIstanbul University
Started2023-04-15
Est. completion2025-10-15
Eligibility
Age18 Years – 90 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05927818

Summary

The primary goal of this prospective study is to define the efficacy of the sentinel lymph node biopsy (SLNB) procedure by comparing it to the results obtained from systematic lymphadenectomy, each performed in participants with a suspicious adnexal mass for early-stage ovarian cancer.

Eligibility

Age: 18 Years – 90 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

Must have a suspicious adnexal mass for early stage ovarian cancer

Must be medically and surgically fit enough to perform SLNB and complete the systematic lymphadenectomy.

\-

Exclusion Criteria:

Ovarian mass with low probability for early stage ovarian cancer.

Medical or surgical contraindications for surgical comprehensive staging.

Metastatic cancers or double primary cancers (metachronous) of ovary

Recurrent ovarian cancer

Preoperative or intraoperative finding of advanced ovarian cancer (FİGO stage III and IV)

Neoadjuvant ovarian cancer

\-

Conditions3

CancerOvarian CarcinomaSentinel Lymph Node

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.